With a 99.6% newborn vaccination rate far exceeding the global average of 85%, China’s hepatitis B prevention program has become one of the world’s most successful public health initiatives, reducing HBV prevalence in children under five to just 0.30% and preventing millions of future liver cancer deaths - a model that the World Health Organization has recognized as a blueprint for other nations.
The Hepatitis B Challenge: Why China’s Success Matters Globally
Hepatitis B virus (HBV) infection remains one of the world’s most significant public health challenges. An estimated 296 million people globally are living with chronic HBV infection, and the virus causes approximately 820,000 deaths annually from liver cirrhosis and hepatocellular carcinoma (liver cancer).
China bore a particularly heavy burden. Before the vaccination era, China had one of the world’s highest HBV prevalence rates, with approximately 10% of the population infected. With 75 million current HBV carriers, the country faced not only an immense health challenge but also significant economic costs from liver disease treatment and lost productivity.
The stakes could not have been higher:
- Transmission Risk: HBV is 50-100 times more infectious than HIV
- Chronic Infection: 90% of infants infected at birth become chronic carriers
- Cancer Risk: Chronic HBV infection increases liver cancer risk 15-20 times
- Economic Burden: Liver disease treatment costs billions annually
Against this backdrop, China’s hepatitis B vaccination program represents one of the most significant public health achievements of the 21st century.
Unprecedented Achievement: Numbers That Tell the Story
The statistics of China’s hepatitis B vaccine success are remarkable by any global standard:
Newborn Vaccination Achievement:
- Vaccination Rate: 99.6% of newborns receive the three-dose hepatitis B vaccine series
- First Dose Timeliness: 95.6% receive the critical first dose within 24 hours of birth
- Global Comparison: Far exceeds the global average of 85% for newborn vaccination
Prevalence Reduction:
- General Population: HBsAg prevalence in 1-69 year olds dropped to 5.86% (from ~10%)
- Children Under 5: HBsAg prevalence reduced to just 0.30%
- Prevented Infections: An estimated 120 million chronic HBV infections prevented
- Lives Saved: Millions of future liver cancer deaths prevented
Dr. Margaret Chan, former Director-General of the World Health Organization, described China’s hepatitis B vaccination program as “one of the most successful public health interventions in history” and a model for other countries to follow.
The Program: From Policy to Practice
China’s hepatitis B vaccination success was built on decades of systematic policy development and implementation:
Timeline of Key Milestones:
- 1992: Hepatitis B vaccine incorporated into the National Immunization Program
- 2002: Hepatitis B vaccine made fully free for all newborns in China
- 2005: Universal free vaccination achieved nationwide
- 2009-2011: Catch-up vaccination campaign for children under 15
- 2020: HBsAg prevalence in children under 5 reaches historic low of 0.30%
- 2025: National Action Plan for Viral Hepatitis Prevention and Control (2025-2030) launched
The “0-1-6” Protocol:
Newborns receive three doses of hepatitis B vaccine following a precise schedule:
- First dose: Within 24 hours of birth (the critical “birth dose”)
- Second dose: At 1 month of age
- Third dose: At 6 months of age
For babies born to HBV-positive mothers, an additional hepatitis B immunoglobulin (HBIG) injection is given within 12 hours of birth, combined with the vaccine, to provide immediate passive immunity while the vaccine generates active immunity.
This combination approach has proven extraordinarily effective in preventing mother-to-child transmission, which was previously the primary route of HBV infection in China.
Global Impact: A Model for the World
China’s hepatitis B vaccination success has had profound implications beyond its borders:
WHO Recognition:
- China’s program featured as a case study in WHO global hepatitis reports
- WHO Western Pacific Region adopted China’s strategies as regional targets
- International delegations regularly visit China to study the vaccination infrastructure
Lessons for Other Countries:
- Universal Access: Free vaccination removes economic barriers to protection
- Birth Dose Importance: The first 24-hour dose is critical for preventing perinatal transmission
- Healthcare Integration: Embedding vaccination in maternal-child health services ensures high coverage
- Sustained Commitment: Long-term political and financial commitment is essential
Contribution to Global Goals:
- China’s success contributes significantly to WHO’s goal of eliminating hepatitis B as a public health threat by 2030
- The reduction in Chinese HBV prevalence has global implications for reducing the pool of transmissible infections
- China’s experience informs global vaccination policy and implementation strategies
Remaining Challenges: The Adult Vaccination Gap
Despite remarkable success in protecting newborns and children, significant challenges remain in extending protection to adults:
Adult Vaccination Gap:
- Overall Adult Rate: Only 26.27% of adults have received hepatitis B vaccination (2011-2021 data)
- Under 40: 36.93% vaccination rate
- Over 40: Just 17.09% vaccination rate
Consequences of the Gap:
- Adults remain vulnerable to new HBV infections through occupational exposure, healthcare procedures, and household contact
- Many adults discover HBV infection only after developing liver cirrhosis or cancer
- The adult reservoir of infection maintains transmission risk to unvaccinated individuals
Addressing the Challenge:
The new National Action Plan for Viral Hepatitis Prevention and Control (2025-2030) specifically targets this gap through:
- Expanded adult vaccination services at community health centers
- Integration of hepatitis B screening into routine adult health examinations
- Targeted vaccination for high-risk groups (healthcare workers, family members of carriers)
- Innovative service delivery models like “prescription vaccination” at primary care visits
Future Direction: Toward Hepatitis B Elimination
China is now positioned to move from controlling hepatitis B to eliminating it as a public health threat:
The 2030 Elimination Goals:
- Reduce new infections: 90% reduction in new chronic HBV infections
- Reduce mortality: 65% reduction in HBV-related deaths
- Diagnosis coverage: 90% of people with chronic HBV diagnosed
- Treatment coverage: 80% of eligible people with chronic HBV treated
Key Strategies:
- Maintain Child Coverage: Sustain the 99%+ newborn vaccination rate
- Expand Adult Coverage: Scale up adult vaccination programs
- Improve Diagnosis: Expand screening and testing programs
- Enhance Treatment: Increase access to antiviral therapy for chronic carriers
- Strengthen Surveillance: Monitor progress and identify gaps
Innovation in Service Delivery:
Zhejiang Province has pioneered the “preventive vaccination health prescription” model, where community doctors can simultaneously issue treatment prescriptions, health guidance, and vaccination orders during a single visit. This integrated approach is being expanded nationally to improve adult vaccination coverage.
The recent return of imported hepatitis B vaccines to the Chinese market, with first doses already administered in Yunnan, Ningxia, Shanxi, and Chongqing, provides additional options for patients and parents. The availability of both domestic and imported vaccines offers flexibility in immunization strategies.
As experts emphasize, the journey from “birth first dose” to “protection for life” requires sustained commitment from policymakers, healthcare providers, and individuals alike. When proactive prevention becomes society’s consensus and action, the goal of eliminating hepatitis B harm will ultimately become reality - a reality that China has demonstrated is achievable.